Literature DB >> 32368721

Prediction of drug combination effects with a minimal set of experiments.

Aleksandr Ianevski1,2, Anil K Giri1, Prson Gautam1, Alexander Kononov1, Swapnil Potdar1, Jani Saarela1, Krister Wennerberg1,3, Tero Aittokallio1,2,4.   

Abstract

High-throughput drug combination screening provides a systematic strategy to discover unexpected combinatorial synergies in pre-clinical cell models. However, phenotypic combinatorial screening with multi-dose matrix assays is experimentally expensive, especially when the aim is to identify selective combination synergies across a large panel of cell lines or patient samples. Here we implemented DECREASE, an efficient machine learning model that requires only a limited set of pairwise dose-response measurements for accurate prediction of drug combination synergy and antagonism. Using a compendium of 23,595 drug combination matrices tested in various cancer cell lines, and malaria and Ebola infection models, we demonstrate how cost-effective experimental designs with DECREASE capture almost the same degree of information for synergy and antagonism detection as the fully-measured dose-response matrices. Measuring only the diagonal of the matrix provides an accurate and practical option for combinatorial screening. The open-source web-implementation enables applications of DECREASE to both pre-clinical and translational studies.

Entities:  

Keywords:  dose-response landscapes; drug combination effects; high-throughput screening; open-source software; supervised machine learning

Year:  2019        PMID: 32368721      PMCID: PMC7198051          DOI: 10.1038/s42256-019-0122-4

Source DB:  PubMed          Journal:  Nat Mach Intell


  40 in total

1.  Molecularly targeted drug combinations demonstrate selective effectiveness for myeloid- and lymphoid-derived hematologic malignancies.

Authors:  Stephen E Kurtz; Christopher A Eide; Andy Kaempf; Vishesh Khanna; Samantha L Savage; Angela Rofelty; Isabel English; Hibery Ho; Ravi Pandya; William J Bolosky; Hoifung Poon; Michael W Deininger; Robert Collins; Ronan T Swords; Justin Watts; Daniel A Pollyea; Bruno C Medeiros; Elie Traer; Cristina E Tognon; Motomi Mori; Brian J Druker; Jeffrey W Tyner
Journal:  Proc Natl Acad Sci U S A       Date:  2017-08-07       Impact factor: 11.205

Review 2.  Combinatorial drug therapy for cancer in the post-genomic era.

Authors:  Bissan Al-Lazikani; Udai Banerji; Paul Workman
Journal:  Nat Biotechnol       Date:  2012-07-10       Impact factor: 54.908

3.  Patient-Customized Drug Combination Prediction and Testing for T-cell Prolymphocytic Leukemia Patients.

Authors:  Liye He; Jing Tang; Emma I Andersson; Sanna Timonen; Steffen Koschmieder; Krister Wennerberg; Satu Mustjoki; Tero Aittokallio
Journal:  Cancer Res       Date:  2018-02-26       Impact factor: 12.701

Review 4.  The potential of biologics for the treatment of asthma.

Authors:  Girolamo Pelaia; Alessandro Vatrella; Rosario Maselli
Journal:  Nat Rev Drug Discov       Date:  2012-12       Impact factor: 84.694

5.  Systematic discovery of drug interaction mechanisms.

Authors:  Guillaume Chevereau; Tobias Bollenbach
Journal:  Mol Syst Biol       Date:  2015-04-29       Impact factor: 11.429

6.  Identification of selective cytotoxic and synthetic lethal drug responses in triple negative breast cancer cells.

Authors:  Prson Gautam; Leena Karhinen; Agnieszka Szwajda; Sawan Kumar Jha; Bhagwan Yadav; Tero Aittokallio; Krister Wennerberg
Journal:  Mol Cancer       Date:  2016-05-10       Impact factor: 27.401

7.  Synergistic drug combinations tend to improve therapeutically relevant selectivity.

Authors:  Joseph Lehár; Andrew S Krueger; William Avery; Adrian M Heilbut; Lisa M Johansen; E Roydon Price; Richard J Rickles; Glenn F Short; Jane E Staunton; Xiaowei Jin; Margaret S Lee; Grant R Zimmermann; Alexis A Borisy
Journal:  Nat Biotechnol       Date:  2009-07-05       Impact factor: 54.908

8.  Identification of Synergistic, Clinically Achievable, Combination Therapies for Osteosarcoma.

Authors:  Diana Yu; Elliot Kahen; Christopher L Cubitt; Jeremy McGuire; Jenny Kreahling; Jae Lee; Soner Altiok; Conor C Lynch; Daniel M Sullivan; Damon R Reed
Journal:  Sci Rep       Date:  2015-11-25       Impact factor: 4.379

9.  Chemogenomics and orthology-based design of antibiotic combination therapies.

Authors:  Sriram Chandrasekaran; Melike Cokol-Cakmak; Nil Sahin; Kaan Yilancioglu; Hilal Kazan; James J Collins; Murat Cokol
Journal:  Mol Syst Biol       Date:  2016-05-24       Impact factor: 11.429

10.  SynergyFinder: a web application for analyzing drug combination dose-response matrix data.

Authors:  Aleksandr Ianevski; Liye He; Tero Aittokallio; Jing Tang
Journal:  Bioinformatics       Date:  2017-08-01       Impact factor: 6.937

View more
  23 in total

1.  Computational Pipeline for Rational Drug Combination Screening in Patient-Derived Cells.

Authors:  Paschalis Athanasiadis; Aleksandr Ianevski; Sigrid S Skånland; Tero Aittokallio
Journal:  Methods Mol Biol       Date:  2022

2.  SYNPRED: prediction of drug combination effects in cancer using different synergy metrics and ensemble learning.

Authors:  António J Preto; Pedro Matos-Filipe; Joana Mourão; Irina S Moreira
Journal:  Gigascience       Date:  2022-09-26       Impact factor: 7.658

3.  SynergyFinder 3.0: an interactive analysis and consensus interpretation of multi-drug synergies across multiple samples.

Authors:  Aleksandr Ianevski; Anil K Giri; Tero Aittokallio
Journal:  Nucleic Acids Res       Date:  2022-05-17       Impact factor: 19.160

4.  A scalable, open-source implementation of a large-scale mechanistic model for single cell proliferation and death signaling.

Authors:  Cemal Erdem; Arnab Mutsuddy; Ethan M Bensman; William B Dodd; Michael M Saint-Antoine; Mehdi Bouhaddou; Robert C Blake; Sean M Gross; Laura M Heiser; F Alex Feltus; Marc R Birtwistle
Journal:  Nat Commun       Date:  2022-06-21       Impact factor: 17.694

5.  Elevated NF-κB/SHh/GLI1 Signature Denotes a Worse Prognosis and Represent a Novel Potential Therapeutic Target in Advanced Prostate Cancer.

Authors:  Davide Vecchiotti; Daniela Verzella; Mauro Di Vito Nolfi; Daniel D'Andrea; Irene Flati; Barbara Di Francesco; Jessica Cornice; Edoardo Alesse; Daria Capece; Francesca Zazzeroni
Journal:  Cells       Date:  2022-07-05       Impact factor: 7.666

6.  bayesynergy: flexible Bayesian modelling of synergistic interaction effects in in vitro drug combination experiments.

Authors:  Leiv Rønneberg; Andrea Cremaschi; Robert Hanes; Jorrit M Enserink; Manuela Zucknick
Journal:  Brief Bioinform       Date:  2021-11-05       Impact factor: 11.622

Review 7.  Machine learning approaches for drug combination therapies.

Authors:  Betül Güvenç Paltun; Samuel Kaski; Hiroshi Mamitsuka
Journal:  Brief Bioinform       Date:  2021-11-05       Impact factor: 11.622

8.  Machine learning methods, databases and tools for drug combination prediction.

Authors:  Lianlian Wu; Yuqi Wen; Dongjin Leng; Qinglong Zhang; Chong Dai; Zhongming Wang; Ziqi Liu; Bowei Yan; Yixin Zhang; Jing Wang; Song He; Xiaochen Bo
Journal:  Brief Bioinform       Date:  2022-01-17       Impact factor: 11.622

9.  SynergyFinder 2.0: visual analytics of multi-drug combination synergies.

Authors:  Aleksandr Ianevski; Anil K Giri; Tero Aittokallio
Journal:  Nucleic Acids Res       Date:  2020-07-02       Impact factor: 16.971

Review 10.  Hyperpolarized Magnetic Resonance and Artificial Intelligence: Frontiers of Imaging in Pancreatic Cancer.

Authors:  José S Enriquez; Yan Chu; Shivanand Pudakalakatti; Kang Lin Hsieh; Duncan Salmon; Prasanta Dutta; Niki Zacharias Millward; Eugene Lurie; Steven Millward; Florencia McAllister; Anirban Maitra; Subrata Sen; Ann Killary; Jian Zhang; Xiaoqian Jiang; Pratip K Bhattacharya; Shayan Shams
Journal:  JMIR Med Inform       Date:  2021-06-17
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.